Please ensure Javascript is enabled for purposes of website accessibility

MannKind Corporation Is Skyrocketing Today, and Here's Why

By Brian Feroldi - Apr 11, 2016 at 12:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares jump in response to the announcement of a special investor call.

IMAGE SOURCE: MANNKIND.

What: Shares of MannKind Corporation (MNKD -2.85%), a biopharmaceutical company primarily focused on treating diabetes, are up more than 20% as of 10:30 a.m. ET on huge volume after the company announced that it will be holding a special conference call with investors to share more details about its future commercialization plans for Afrezza.

So what: MannKind has been in a holding pattern for months since its former partner Sanofi (SNY -0.63%) stated that they would be returning the rights to market Afrezza back to the company. Since then, bulls have been patiently waiting for MannKind to regain Afrezza's marketing rights so the company can finally start to address the issues that caused Afrezza's sales to be much lower than initially hoped for.

While Afrezza was still under Sanofi's control, there was little that MannKind could do to fix any of the problems that plagued its launch beyond give a few hints at their proposed sales and marketing strategy.

Thankfully, news finally broke on April 5 that MannKind has officially regained the rights to commercialize Afrezza from Sanofi, putting the company's destiny back into its own hands.

To give investors more clarity about its sales marketing strategy, MannKind announced today that it will be holding a special investor call on April 19 at 5 p.m. ET, when it will share details about its plans to commercialize Afrezza in the U.S.

The press release was light on details but it did promise more information about its plans to expand patient access to Afrezza and provide a timeline of its relaunch. MannKind also confirmed that it will begin to distribute Afrezza through its own channels sometime during the third quarter. Until then, patients will still be able to access the drug through Sanofi's current distribution system. 

Separately, the company said that it will be holding its first-quarter investor call on May 9 to provide financial projections for 2016 and beyond. 

Now what: MannKind's stock has been wildly volatile over the past few months, regularly rising and falling by double digits on very little news. That's likely owed to the fact that this stock has an enormous short position against it. As of the middle of March, roughly 120 million shares of stock had been sold short, which represents roughly 44% of its publicly traded float.

Despite today's share price action, the only question that matters moving forward is this: Will MannKind be successful enough with Afrezza's relaunch to fix its financial situation? While there are likely to be a number of levers that management can pull to spur demand for Afrezza -- the largest one of which is likely to be a price cut -- it's unknown if that will be enough to turn around the company's fortunes and fix its financial position.

We won't know the answer to that question for at least several more months, which means that MannKind's shares are likely to remain extremely volatile. Bulls and bears alike should plan accordingly.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
Sanofi
SNY
$55.15 (-0.63%) $0.35
MannKind Corporation Stock Quote
MannKind Corporation
MNKD
$4.44 (-2.85%) $0.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.